UBS
ESPR icon

UBS’s Esperion Therapeutics ESPR Stock Holding History

UBS’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$17K Buy
666
+547
+460% +$8.69K ﹤0.01% 8191
2014
Q2 		$2K Sell
119
-41
-26% -$592 ﹤0.01% 10020
2014
Q1 		$3K Buy
160
+47
+42% +$730 ﹤0.01% 9832
2013
Q4 		$2K Sell
113
-117
-51% -$1.7K ﹤0.01% 10021
2013
Q3 		$4K Buy
+230
New +$3.86K ﹤0.01% 9556

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EverPoint Asset Management
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS's ESPR Position: Q3 2014 in Review

UBS increased its Esperion Therapeutics (ESPR) stake by 460% in Q3 2014, buying an estimated $8.69K and bringing the position to 666 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #8191.

UBS first reported a position in ESPR in Q3 2013 and has held it in 5 quarters since. 50 funds tracked by Wall St. Rank hold ESPR as of Q3 2014.

  • UBS held 666 shares of Esperion Therapeutics worth $17K as of Q3 2014.
  • UBS bought 547 Esperion Therapeutics shares in Q3 2014, an estimated $8.69K.
  • Esperion Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8191 holding.
  • UBS first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 5 quarters since.
  • 50 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.